Boop pneumonia survival rate full#
Boop pneumonia survival rate series#

All patients received prednisone at 1 mg/kg PO and experienced rapid improvement: they were weaned off ventilatory support and discharged within a few days.

A similar pattern of OP was observed in each of the CT scans. For further evaluation of other reasons why these patients were not improving, CT scans of the chest were ordered. Notwithstanding, little progress had been made in their clinical status.

All of them received a 10-day course of dexamethasone, broad-spectrum antibiotics, and continuous positive airway pressure. Our clinical scenarios encompassed patients diagnosed with the novel coronavirus and in need of oxygen support.

Boop pneumonia survival rate full#

He was finally discharged on day 11 of prednisone use after a full recovery. He rapidly experienced significant improvement in both symptoms and laboratory tests. Soon after being started on prednisone at 1 mg/kg PO, CPAP was stopped, and oxygen support was switched to low-flow nasal cannula. He then underwent a CT scan, which revealed a pattern compatible with OP ( Fig. Throughout the following 10 days (on illness day 21), his P/F ratio on arterial blood gas trended upwards from 85 to 230 despite sustaining dyspnea, fever, leukocytosis, and high titers of C-reactive protein. Four days later, continuous positive airway pressure (CPAP) was also started. On day 1 of hospitalization, he was started on a daily dose of dexamethasone at 6 mg PO. A chest X-ray (CXR) upon admission showed a slight infiltrate on the right lower lobe. Prior to admission, he had used azithromycin and amoxicillin-clavulanate. He had a positive RT-PCR for SARS-CoV-2 on the 11th day of symptoms. His prior medical record was unremarkable. Case reports Patient 1ĥ2-year-old white male. To the best of our knowledge, this is the first report to analyze this issue.

Boop pneumonia survival rate series#

Herein we report a series of three cases with OP that responded dramatically to corticosteroids. 5 The question of whether an approach with a high dose of corticosteroids would be beneficial for patients with OP secondary to COVID-19 remains to be answered.

3,6Ĭorticosteroids are the standard therapy for OP, and patients usually experience pronounced clinical response within a few days. 5 Viral infections are among the most common etiologies of secondary OP. It is histologically defined as an intra-alveolar organized exudate composed of myofibroblasts and connective tissue with variable interstitial inflammation. OP consists of granulation tissue and proliferation of fibroblasts within the lung parenchyma. Main tomographic findings include ground-glass opacities, consolidation, reticulation, and parenchymal distortion. 1 Additionally, the pattern of organizing pneumonia (OP) on computed tomography (CT) scan of the chest has been reported, mostly as a late phase complication. In patients suffering from COVID-19, lung involvement is most commonly characterized by ground-glass opacification with or without consolidative abnormalities, consistent with viral pneumonia. Our report suggests that patients with COVID-19 with organizing pneumonia might benefit from high dose corticosteroids as an adjuvant therapy. They were discharged after a mean period of 6.3 days of hospitalization. The patients were treated with a high dose of corticosteroids (prednisone 1 mg/kg PO), showing marked clinical improvement, and decreasing oxygen flow ratio demand. The patients underwent chest computed tomography scans due to maintained hypoxemia, which showed a pattern compatible with organizing pneumonia. Herein we report a series of three patients, one male and two females, mean age 58.3 years old, admitted for COVID-19 with severe pulmonary disease requiring ventilatory support. Corticosteroids are standard therapy for organizing pneumonia, but the question of whether an approach with high dose corticosteroids would be beneficial for patients with organizing pneumonia secondary to COVID-19 remains to be answered. Organizing pneumonia emerges as a late phase complication of COVID-19.